Founder's Take: A Bioactive Moisturizer During Acne Therapy

TL;DR: A 40-participant randomized, investigator-blind, split-face trial compared a bioactive moisturizer with a traditional moisturizer in patients using adapalene/benzoyl peroxide gel or oral isotretinoin. The bioactive side had higher hydration, less dryness, and higher satisfaction. Acne lesions improved similarly on both sides, so this is a barrier-comfort story, not a superior acne-clearing claim.

Bottom line for your skin: Most relevant to people whose acne treatment makes skin feel dry, tight, flaky, rough, or uncomfortable. The result supports adjunctive moisturizer benefits, not acne treatment replacement.

Effect-Size Graphic

The bars show the size of the reported signal within this post only. They are not meant to compare different measurement scales across studies.

Hydration reported signal
Higher with bioactive side; p=0.001
Best support for less dry-looking skin.
Dryness reported signal
Less dryness; p=0.021
Visible and sensory endpoint.
Satisfaction reported signal
Higher satisfaction; p=0.004
Useful because tolerability affects adherence.
Acne lesions reported signal
Decreased equally on both sides
No superior acne-clearing claim.

Key Outcomes / Results

Outcome Reported result How to read it
Hydration Higher hydration on the bioactive-moisturizer side versus traditional moisturizer; p=0.001. Maps well to dryness, flaking, and a smoother-looking surface.
Dryness Traditional moisturizer scored worse for dryness; p=0.021. Less dryness usually means skin feels less tight and looks less rough.
Patient satisfaction Higher satisfaction with the bioactive moisturizer; p=0.004. A practical endpoint for acne regimens because irritation often drives nonadherence.
Barrier stress TEWL increased more with the traditional moisturizer, favoring the bioactive side. Supports a barrier-comfort interpretation.
Acne lesions Lesion counts decreased on both sides without a meaningful between-side advantage. Do not claim superior acne clearing from this moisturizer study.

The Study

  • Paper: The efficacy of a bioactive moisturizer in mitigating side effects of acne therapies: a randomized, investigator-blind, split-face trial.
  • Journal: Dermatology Reports. Published 2026.
  • Population: 40 Asian patients using adapalene/benzoyl peroxide gel or oral isotretinoin.
  • Design: randomized split-face comparison over weeks 0, 2, and 4.
  • Tested formula included barrier- and comfort-oriented ingredients such as ceramide, panthenol, licochalcone A, and 4-t-butylcyclohexanol.

Dermatologist/Researcher Interpretation

This is exactly the kind of moisturizer study that matters in real life: acne therapy can work, but dryness and irritation can make people stop using it. A moisturizer does not have to clear acne better to be clinically useful.

The hydration, dryness, TEWL, and satisfaction findings all point in the same direction: the bioactive moisturizer made the treatment period more comfortable for skin. That could show up as less flaking, less tightness, and a smoother-looking surface.

The acne-lesion result is the claim boundary. Lesions improved on both sides, so the moisturizer should be framed as supportive care during acne therapy, not as an acne-clearing active.

What this means for product claims

Reasonable claim: the tested bioactive moisturizer improved hydration, reduced dryness, and improved satisfaction during acne therapy. Too far: it clears acne better than standard moisturizer or replaces acne medication.

Key limitations

  • Small 40-participant trial.
  • Short follow-up of 4 weeks.
  • Split-face designs are efficient but can be influenced by application behavior.
  • Result applies to the tested finished moisturizer and acne-regimen context.
  • The paper did not tabulate an intuitive magnitude for every endpoint, so p values should not be treated as effect sizes.

Reference

Triwatcharikorn J, Techamontrikul S, Ngamdumrongkiat N, Rerknimitr P. The efficacy of a bioactive moisturizer in mitigating side effects of acne therapies: a randomized, investigator-blind, split-face trial. Dermatology Reports. 2026. doi: 10.4081/dr.2026.10491. PMID: 41891349.